# A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

> **NCT05084508** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 800 (actual)

## Conditions studied

- Chickenpox

## Interventions

- **BIOLOGICAL:** Investigational varicella vaccine low potency
- **BIOLOGICAL:** Investigational varicella vaccine medium potency
- **BIOLOGICAL:** Investigational varicella vaccine high potency
- **BIOLOGICAL:** Licensed varicella vaccine Lot 1
- **BIOLOGICAL:** Licensed varicella vaccine Lot 2
- **BIOLOGICAL:** Measles, mumps, and rubella vaccine
- **BIOLOGICAL:** Hepatitis A vaccine
- **BIOLOGICAL:** 13-valent pneumococcal conjugate vaccine

## Key facts

- **NCT ID:** NCT05084508
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-03
- **Primary completion:** 2024-02-09
- **Final completion:** 2024-06-13
- **Target enrollment:** 800 (ACTUAL)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05084508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05084508, "A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05084508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*